153 related articles for article (PubMed ID: 33363632)
1. TCR-mimic antibody-drug conjugates targeting intracellular tumor-specific mutant antigen KRAS G12V mutation.
Shen Y; Wei X; Jin S; Wu Y; Zhao W; Xu Y; Pan L; Zhou Z; Chen S
Asian J Pharm Sci; 2020 Nov; 15(6):777-785. PubMed ID: 33363632
[TBL] [Abstract][Full Text] [Related]
2. The Antitumor Activity of TCR-Mimic Antibody-Drug Conjugates (TCRm-ADCs) Targeting the Intracellular Wilms Tumor 1 (WT1) Oncoprotein.
Shen Y; Li YM; Zhou JJ; Zhou Z; Xu YC; Zhao WB; Chen SQ
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31408937
[TBL] [Abstract][Full Text] [Related]
3. Elimination of melanoma by sortase A-generated TCR-like antibody-drug conjugates (TL-ADCs) targeting intracellular melanoma antigen MART-1.
Lai J; Wang Y; Wu SS; Ding D; Sun ZY; Zhang Y; Zhou J; Zhou Z; Xu YC; Pan LQ; Chen SQ
Biomaterials; 2018 Sep; 178():158-169. PubMed ID: 29933102
[TBL] [Abstract][Full Text] [Related]
4. Targeting KRAS
Ai Q; Li F; Zou S; Zhang Z; Jin Y; Jiang L; Chen H; Deng X; Peng C; Mou N; Wen C; Shen B; Zhan Q
Front Immunol; 2023; 14():1161538. PubMed ID: 37287989
[TBL] [Abstract][Full Text] [Related]
5. [Preclinical study of T cell receptor specifically reactive with
Cheng XJ; Jiang D; Zhang LH; Wang JH; Li YZ; Zhai JH; Yan BQ; Zhang LL; Xie XW; Li ZY; Ji JF
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):884-895. PubMed ID: 36241231
[TBL] [Abstract][Full Text] [Related]
6. Potent antitumor activity of a bispecific T-cell engager antibody targeting the intracellular antigen KRAS G12V.
Lu C; Zou L; Wang Q; Sun M; Shi T; Xu S; Meng F; Du J
Biomol Biomed; 2024 May; ():. PubMed ID: 38752985
[TBL] [Abstract][Full Text] [Related]
7. Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen.
Wright KM; DiNapoli SR; Miller MS; Aitana Azurmendi P; Zhao X; Yu Z; Chakrabarti M; Shi W; Douglass J; Hwang MS; Hsiue EH; Mog BJ; Pearlman AH; Paul S; Konig MF; Pardoll DM; Bettegowda C; Papadopoulos N; Kinzler KW; Vogelstein B; Zhou S; Gabelli SB
Nat Commun; 2023 Aug; 14(1):5063. PubMed ID: 37604828
[TBL] [Abstract][Full Text] [Related]
8. KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors.
Lu D; Chen Y; Jiang M; Wang J; Li Y; Ma K; Sun W; Zheng X; Qi J; Jin W; Chen Y; Chai Y; Zhang CWH; Liang H; Tan S; Gao GF
Nat Commun; 2023 Oct; 14(1):6389. PubMed ID: 37828002
[TBL] [Abstract][Full Text] [Related]
9. Development of a T-cell receptor mimic antibody targeting a novel Wilms tumor 1-derived peptide and analysis of its specificity.
Kurosawa N; Midorikawa A; Ida K; Fudaba YW; Isobe M
Cancer Sci; 2020 Oct; 111(10):3516-3526. PubMed ID: 32770595
[TBL] [Abstract][Full Text] [Related]
10. Identification and affinity enhancement of T-cell receptor targeting a KRAS
Zhang M; Xu W; Luo L; Guan F; Wang X; Zhu P; Zhang J; Zhou X; Wang F; Ye S
Commun Biol; 2024 Apr; 7(1):512. PubMed ID: 38684865
[TBL] [Abstract][Full Text] [Related]
11. TCR mimic monoclonal antibody targets a specific peptide/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models.
Verma B; Neethling FA; Caseltine S; Fabrizio G; Largo S; Duty JA; Tabaczewski P; Weidanz JA
J Immunol; 2010 Feb; 184(4):2156-65. PubMed ID: 20065111
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Antibodies against Intracellular Tumor Antigens.
Trenevska I; Li D; Banham AH
Front Immunol; 2017; 8():1001. PubMed ID: 28868054
[TBL] [Abstract][Full Text] [Related]
13. TCR mimic compounds for pHLA targeting with high potency modalities in oncology.
Gerber HP; Presta LG
Front Oncol; 2022; 12():1027548. PubMed ID: 36338746
[TBL] [Abstract][Full Text] [Related]
14. Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death.
Wittman VP; Woodburn D; Nguyen T; Neethling FA; Wright S; Weidanz JA
J Immunol; 2006 Sep; 177(6):4187-95. PubMed ID: 16951384
[TBL] [Abstract][Full Text] [Related]
15. A novel cell line generated using the CRISPR/Cas9 technology as universal quality control material for KRAS G12V mutation testing.
Jia S; Zhang R; Lin G; Peng R; Gao P; Han Y; Fu Y; Ding J; Wu Q; Zhang K; Xie J; Li J
J Clin Lab Anal; 2018 Jun; 32(5):e22391. PubMed ID: 29380513
[TBL] [Abstract][Full Text] [Related]
16. Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma.
Liu C; Liu H; Dasgupta M; Hellman LM; Zhang X; Qu K; Xue H; Wang Y; Fan F; Chang Q; Yu D; Ge L; Zhang Y; Cui Z; Zhang P; Heller B; Zhang H; Shi B; Baker BM; Liu C
Sci Rep; 2022 Jul; 12(1):12068. PubMed ID: 35840635
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
[TBL] [Abstract][Full Text] [Related]
18. T cell receptor mimic antibodies for cancer therapy.
Dubrovsky L; Dao T; Gejman RS; Brea EJ; Chang AY; Oh CY; Casey E; Pankov D; Scheinberg DA
Oncoimmunology; 2016; 5(1):e1049803. PubMed ID: 26942058
[TBL] [Abstract][Full Text] [Related]
19. TCR-like antibody drug conjugates mediate killing of tumor cells with low peptide/HLA targets.
Lowe DB; Bivens CK; Mobley AS; Herrera CE; McCormick AL; Wichner T; Sabnani MK; Wood LM; Weidanz JA
MAbs; 2017; 9(4):603-614. PubMed ID: 28273004
[TBL] [Abstract][Full Text] [Related]
20. Intracellular targets as source for cleaner targets for the treatment of solid tumors.
Gerber HP; Sibener LV; Lee LJ; Gee M
Biochem Pharmacol; 2019 Oct; 168():275-284. PubMed ID: 31323186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
